Compass Therapeutics (NASDAQ:CMPX) Raised to Strong-Buy at Leerink Partnrs

Leerink Partnrs upgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a hold rating to a strong-buy rating in a research note published on Tuesday,Zacks.com reports.

Other research analysts also recently issued reports about the company. Guggenheim reissued a “buy” rating and issued a $12.00 price objective on shares of Compass Therapeutics in a research note on Wednesday. Wedbush reiterated an “outperform” rating and issued a $8.00 target price on shares of Compass Therapeutics in a report on Tuesday. Piper Sandler assumed coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price target on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research report on Tuesday. Finally, Jefferies Financial Group lifted their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, February 10th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $11.63.

Compass Therapeutics Stock Performance

Compass Therapeutics stock opened at $1.69 on Tuesday. The firm has a market cap of $233.70 million, a price-to-earnings ratio of -4.57 and a beta of 1.19. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $4.08. The firm has a 50 day moving average price of $2.81 and a two-hundred day moving average price of $2.11.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, equities research analysts predict that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new position in shares of Compass Therapeutics during the fourth quarter valued at about $35,000. Tang Capital Management LLC raised its holdings in shares of Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company’s stock worth $8,555,000 after acquiring an additional 4,087,005 shares during the last quarter. ProShare Advisors LLC lifted its position in Compass Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after acquiring an additional 9,451 shares in the last quarter. MPM Bioimpact LLC boosted its stake in Compass Therapeutics by 51.9% during the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company’s stock valued at $12,423,000 after purchasing an additional 2,926,002 shares during the last quarter. Finally, Enavate Sciences GP LLC bought a new stake in Compass Therapeutics during the 4th quarter worth approximately $11,293,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.